Verve’s gene editor cuts cholesterol in first-in-human HeFH trial Therapeutics When given at potentially therapeutic doses, Verve’s base editor led to strong reductions in LDL cholesterol and PCSK9 levels in patients with heterozygous familial hypercholesterolemia. Read more November 13, 2023/by BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2023-11-13 08:44:282023-11-13 08:55:56Verve’s gene editor cuts cholesterol in first-in-human HeFH trial
